As new consumer hardware and software capabilities have bumped up against medicine over the last few years, consumers and manufacturers alike have struggled with identifying the line between “wellness” products such as earbuds that can also amplify and clarify surrounding speakers’ voices and regulated medical devices such as conventional hearing aids. On 6 January 2026, the U.S. Food and Drug Administration issued new guidance documents clarifying how it interprets existing law for the review of wearable and AI-assisted devices.

The first document, for general wellness, specifies that the FDA will interpret noninvasive sensors such as sleep trackers or heart rate monitors as low-risk wellness devices while treating invasive devices under conventional regulations. The other document defines how the FDA will exempt clinical-decision support tools from medical device regulations, limiting such software to analyzing existing data rather than extracting data from sensors, and requiring them to enable independent review of their recommendations. The documents do not rewrite any statutes, but they refine interpretation of existing law, compared to the 2019 and 2022 documents they replace. They offer a fresh lens on how regulators see technology that sits at the intersection of consumer electronics, software, and medicine—a category many other countries are choosing to regulate more strictly rather than less.

What the 2026 update changed

The 2026 FDA update clarifies how it distinguishes between “medical information” and systems that measure physiological “signals” or “patterns.” Earlier guidance discussed these concepts more generally, but the new version defines signal-measuring systems as those that collect continuous, near-continuous, or streaming data from the body for medical purposes, such as home devices transmitting blood pressure, oxygen saturation, or heart rate to clinicians. It gives more concrete examples, like a blood glucose lab result as medical information versus continuous glucose monitor readings as signals or patterns.

The updated guidance also sharpens examples of what counts as medical information that software may display, analyze, or print. These include radiology reports or summaries from legally marketed software, ECG reports annotated by clinicians, blood pressure results from cleared devices, and lab results stored in electronic health records.

In addition, the 2026 update softens FDA’s earlier stance on clinical decision tools that offer only one recommendation. While prior guidance suggested tools needed to present multiple options to avoid regulation, FDA now indicates that a single recommendation may be acceptable if only one option is clinically appropriate, though it does not define how that determination will be made.

Separately, updates to the general wellness guidance clarify that some noninvasive wearables—such as optical sensors estimating blood glucose for wellness or nutrition awareness—may qualify as general wellness products, while more-invasive technologies would not.

Wellness still requires accuracy

For designers of wearable health devices, the practical implications go well beyond what label you choose. “Calling something ‘wellness’ doesn’t reduce the need for rigorous validation,” says Omer Inan, a medical device technology researcher at the Georgia Tech School of Electrical and Computer Engineering. A wearable that reports blood pressure inaccurately could lead a user to conclude that their values are normal when they are not, potentially influencing decisions about seeking clinical care.

“In my opinion, engineers designing devices to deliver health and wellness information to consumers should not change their approach based on this new guidance,” says Inan. Certain measurements—such as blood pressure or glucose—carry real medical consequences regardless of how they’re branded, Inan notes.

Unless engineers follow robust validation protocols for technology delivering health and wellness information, Inan says, consumers and clinicians alike face the risk of faulty information.

To address that, Inan advocates for transparency: Companies should publish their validation results in peer-reviewed journals, and independent third parties without financial ties to the manufacturer should evaluate these systems. That approach, he says, helps the engineering community and the broader public assess the accuracy and reliability of wearable devices.

When wellness meets medicine

The societal and clinical impacts of wearables are already visible, regardless of regulatory labels, says Sharona Hoffman, JD, a law and bioethics professor at Case Western Reserve University.

Medical metrics from devices like the Apple Watch or Fitbit may be framed as “wellness,” but in practice many users treat them like medical data, influencing their behavior or decisions about care, Hoffman points out.

“It could cause anxiety for patients who constantly check their metrics,” she notes. Alternatively, “A person may enter a doctor’s office confident that their wearable has diagnosed their condition, complicating clinical conversations and decision-making.”

Moreover, privacy issues remain unresolved, unmentioned in previous or updated guidance documents. Many companies that design wellness devices fall outside protections like the Health Insurance Portability and Accountability Act (HIPAA), meaning data about health metrics could be collected, shared, or sold without the same constraints as traditional medical data. “We don’t know what they’re collecting information about or whether marketers will get hold of it,” Hoffman says.

International approaches

The European Union’s Artificial Intelligence Act designates systems that process health-related data or influence clinical decisions as “high risk,” subjecting them to stringent requirements around data governance, transparency, and human oversight. China and South Korea have also implemented rules that tighten controls on algorithmic systems that intersect with health care or public-facing use cases. South Korea provides very specific categories for regulation for technology makers, such as standards on labeling and descriptions on medical devices and good manufacturing practices.

Across these regions, regulators are not only classifying technology by its intended use but also by its potential impact on individuals and society at large.

“Other countries that emphasize technology are still worrying about data privacy and patients,” Hoffman says. “We’re going in the opposite direction.”

Post-market oversight

“Regardless of whether something is FDA approved, these technologies will need to be monitored in the sites where they’re used,” says Todd R. Johnson, a professor of biomedical informatics at the McWilliams School of Biomedical Informatics at UTHealth Houston, who has worked on FDA-regulated products and informatics in clinical settings. “There’s no way the makers can ensure ahead of time that all of the recommendations will be sound.”

Large health systems may have the capacity to audit and monitor tools, but smaller clinics often do not. Monitoring and auditing are not emphasized in the current guidance, raising questions about how reliability and safety will be maintained once devices and software are deployed widely.

Balancing innovation and safety

For engineers and developers, the FDA’s 2026 guidance presents both opportunities and responsibilities. By clarifying what counts as a regulated device, the agency may reduce upfront barriers for some categories of technology. But that shift also places greater weight on design rigor, validation transparency, and post-market scrutiny.

“Device makers do care about safety,” Johnson says. “But regulation can increase barriers to entry while also increasing safety and accuracy. There’s a trade-off.”